(Q34422694)

2 August 2017

1 reference

title

Management of interferon therapy nonresponders (English)

1 reference

2 August 2017

Shiffman ML

1

1 reference

2 August 2017

publication date

1 November 2001

1 reference

2 August 2017

published in

Clinics in liver disease

1 reference

2 August 2017

volume

5

1 reference

2 August 2017

issue

4

1 reference

2 August 2017

page(s)

1025-1043

1 reference

Interferon-alpha plus ribavirin in chronic hepatitis C resistant to previous interferon-alpha course: results of a randomized multicenter trial.

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Efficacy of combination therapy with amantadine, thymosin alpha 1 and alpha/beta interferon in mice infected with influenza A virus

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Dose increase augments response rate to interferon-alpha in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis c: pretreatment stratification by viral burden and genotype

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Use and interpretation of HCV diagnostic tests in the clinical setting

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Combination antiviral therapy for respiratory virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Re-treatment of chronic hepatitis C with consensus interferon .

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Hepatitis C in African Americans: summary of a workshop

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Comparison of quantitative HCV RNA assays in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Ursodeoxycholic acid therapy in hepatobiliary disease

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Hepatitis C kinetics: mathematical modeling of viral response to therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Therapy of hepatitis C: overview

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Quantitative measurement of serum HCV RNA in patients with chronic hepatitis C: comparison between Amplicor HCV monitor system and branched DNA signal amplification assay.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Ursodeoxycholic acid treatment of gallstones. Dose-response study and possible mechanism of action

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Intrahepatic hepatitis C RNA levels do not correlate with degree of liver injury in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Amantadine for influenza A.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Loss of serum HCV RNA at week 4 of interferon‐α therapy is associated with more favorable long‐term response in patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Interferon resistance of hepatitis C virus genotype 1b: relationship to nonstructural 5A gene quasispecies mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Measuring hepatitis C viremia in clinical samples: Can we trust the assays?

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Multicenter Study Group under the coordination of the Necker Hospital, Paris, Franc

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Evolution of hepatitis C virus quasispecies in hypervariable region 1 and the putative interferon sensitivity-determining region during interferon therapy and natural infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Interleukin-10 modulates type I collagen and matrix metalloprotease gene expression in cultured human skin fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Interferon versus ribavirin plus interferon in chronic hepatitis C previously resistant to interferon: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Pegylated interferons: what role will they play in the treatment of chronic hepatitis C?

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. The Virginia Cooperative Hepatitis Treatment Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Use of granulocyte macrophage colony stimulating factor alone or in combination with interferon-alpha-2b for treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Prophylaxis against gallstone formation with ursodeoxycholic acid in patients participating in a very-low-calorie diet program

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Decrease in Serum Hepatitis C Viral RNA during Alpha-Interferon Therapy for Chronic Hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Treatment of chronic hepatitis C with amantadine

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

A multicenter, placebo-controlled, randomized, double-blind, prospective trial of prophylactic ursodiol for the prevention of gallstone formation following gastric-bypass-induced rapid weight loss

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Alpha-interferon therapy for non-A, non-B hepatitis transmitted by gammaglobulin replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Long-term re-treatment with interferon and ribavirin combination therapy in patients with chronic hepatitis C who are non-responders to interferon alone: a preliminary study

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Expression of interleukin-10 by in vitro and in vivo activated hepatic stellate cells

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

The long-term pathological evolution of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

A randomized, double-blind controlled trial of interferon alpha-2b and ribavirin vs. interferon alpha-2b and amantadine for treatment of chronic hepatitis C non-responder to interferon monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Reliability of polymerase chain reaction for detection of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Peginterferon alfa-2a in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970207-5

7 January 2021

10.1016/S1089-3261(05)70207-5

Identifiers

DOI

1 reference

2 August 2017

1 reference